ReShape Lifesciences Inc.
RSLS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.34M
Close$
Share Statistics
| Market cap | $2.34 Million |
|---|---|
| Enterprise Value | $-6,434,994.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 1.9 |
| Outstanding Shares | 0 |
Return
| Return on Equity | -145.78% |
|---|---|
| Return on Assets | -115.09% |
| Return on Invested Capital | -139.72% |
Valuation & Multiples
| P/E Ratio | -1.05 |
|---|---|
| PEG | 0.63 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.45 |
| Enterprise Value to EBIT | 0.57 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 18, 2025
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ReShape Lifesciences Inc.
2 employees
CEO: Andrew Rasdal Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.